Pamorelin (Triptorelin)

Triptorelin, the active ingredient in Pamorelin, is a gonadotropin-releasing hormone (GnRH) agonist presented as a sterile powder for solution for injection use. It is used in the management of hormone‑dependent conditions such as prostate cancer, endometriosis and assisted reproductive technology protocols. GNH USA supplies Pamorelin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

GNH USA supplies Pamorelin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Pamorelin is a GnRH‑agonist that modulates the hypothalamic‑pituitary‑gonadal axis in several hormone‑sensitive conditions.

- Prostate cancer: provides sustained testosterone suppression to slow tumor progression. - Endometriosis: reduces estrogen production, alleviating pelvic pain and lesion growth. - Assisted reproduction: controls ovarian stimulation timing during in‑vitro fertilisation cycles. - Precocious puberty: delays early sexual development by suppressing gonadotropin release. - Uterine fibroids: decreases fibroid size and bleeding by lowering systemic estrogen levels.

Triptorelin may cause a range of adverse reactions, most of which are related to the rapid hormonal changes it induces.

Common Side Effects: - Hot‑flashes - Headache - Injection site pain or erythema - Fatigue - Nausea - Mood swings

Serious or Rare Side Effects: - Severe hypo‑gonadism leading to bone mineral density loss - Cardiovascular events such as myocardial infarction or stroke - Allergic anaphylaxis - Severe hepatic dysfunction - Pituitary apoplexy (very rare) - Persistent severe injection‑site reactions

Triptorelin should be used under the supervision of a qualified healthcare professional familiar with hormonal therapies.

- Monitor hormone levels: regular assessment of testosterone or estradiol is required to confirm adequate suppression. - Bone health: assess bone mineral density periodically, especially in long‑term use. - Cardiovascular risk: evaluate history of heart disease before initiating therapy. - Pregnancy and lactation: contraindicated in women who are pregnant or breastfeeding. - Drug interactions: review concomitant medications that may affect hormone metabolism. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Trip...